Community Health Interventions for Renal Disease
(INSPIRE Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your healthcare provider.
What data supports the effectiveness of the treatment Community Health Worker Assistance for renal disease?
Community health worker (CHW) interventions have been shown to improve health outcomes for Latinx individuals with kidney disease by building trust, enabling self-help, and using a trauma-informed approach. Additionally, CHWs have been effective in helping patients with diabetes and hypertension manage their conditions, suggesting they can also support people with kidney disease.12345
Is the Community Health Worker Assistance intervention safe for humans?
How does the Community Health Worker intervention differ from other treatments for renal disease?
This treatment is unique because it involves community health workers (CHWs) who provide culturally relevant support and education, helping patients navigate the healthcare system and access resources, which is particularly beneficial for Latinx populations at higher risk for kidney disease. Unlike traditional medical treatments, this approach focuses on building trust and empowering patients to manage their health more effectively.12111213
What is the purpose of this trial?
This is a cluster randomized controlled clinical trial evaluating the effect of community health workers (CHWs) and provider education on kidney transplant (KTx) waitlisting compared to usual care (waitlist control). CKD/HD providers will be randomized to intervention or control, and all patients with the same providers will be in the same randomization group. CHWs will address unmet social needs and patient symptoms through evaluations and linkage to clinical and community services. Intervention providers will receive education, which will include training on working with CHWs, reducing bias in clinical decision-making, and increasing affirming/reducing stigmatizing language in electronic health records (EHRs).
Research Team
Lili Chan
Principal Investigator
Ichan School of Medicine at Mount Sinai Hospital
Eligibility Criteria
This trial is for patients with renal disease who are under the care of CKD/HD providers. Participants will be grouped based on their provider's random assignment to either the intervention or control group. The study aims to help those facing social challenges that affect their health.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive support from community health workers and provider education to assist with the kidney transplant process
Follow-up
Participants are monitored for safety and effectiveness after intervention
Extension
Participants in the usual care group receive education and limited CHW support at the end of the study
Treatment Details
Interventions
- Community Health Worker Assistance
- Intervention Providers
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator